UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

August 24, 2023

Panelists wrap up their discussion on HER2+ breast cancer by summarizing the most exciting recent advances in the field and their hopes for the future of treatment.

August 23, 2023

Monica D. Mead, MD, discusses the impact of key data on the role of ibrutinib in the treatment of mantle cell lymphoma.

August 21, 2023

Monica D. Mead, MD, discusses the evolving use of the BTK inhibitors in the treatment of patients with MCL, the factors for selecting between ibrutinib, zanubrutinib, and acalabrutinib, and unmet needs for patients with MCL.

August 17, 2023

Dr Kaklamani presents a profile of a patient with HER2+ breast cancer and liver metastases who had disease progression after first-line chemotherapy and a solitary new brain metastasis after second-line T-DM1.

August 17, 2023

Melinda L. Telli, MD, presents a profile of a patient with early stage breast cancer with residual nodal disease after neoadjuvant chemotherapy and surgery, whose tumor was initially HER2+ but became triple-negative after treatment.

August 10, 2023

The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.

August 10, 2023

Virginia G. Kaklamani, MD, DSc, presents a patient profile of early stage HER2+ breast cancer with residual nodal disease after neoadjuvant chemotherapy and surgery.

August 10, 2023

Experts share their go-to regimens in the third-line and higher setting of HER2+ metastatic breast cancer, and touch on the factors that support their decision-making.

August 10, 2023

An overview of ongoing research in the endometrial cancer treatment space.

August 09, 2023

Dana Chase, MD, FACOG, discusses key efficacy, safety, and quality of life data from the RUBY trial supporting the FDA approval of dostarlimab and explains how this approval could help improve the efficacy of current chemotherapy regimens in advanced-stage or recurrent endometrial cancer.

August 03, 2023

Debu Tripathy, MD, discusses novel therapies being developed for later-line treatment of HER2+ mBC.

August 03, 2023

The expert panel reviews the KEYNOTE-775 trial, which focused on lenvatinib and pembrolizumab in advanced endometrial cancer.

August 03, 2023

Drs McArthur and Telli discuss recent data updates from the DESTINY-Breast trials of T-DXd, including a pooled analysis, and share best practices for monitoring patients for lung complications.

August 03, 2023

A panel of gynecologic oncologists review the PHAEDRA study and discuss the overall treatment landscape for endometrial cancer.

July 27, 2023

Drs Tripathy and Kaklamani emphasize the most critical unmet needs for patients with HER2+ metastatic breast cancer in the third-line or higher settings and recap what the field previously learned from the HER2CLIMB trial of tucatinib/trastuzumab/capecitabine.

July 27, 2023

Experts on endometrial cancer review the NRG-GY018 and RUBY clinical trials.

July 27, 2023

Panelists briefly touch on ongoing trials of second-line tucatinib combination therapy, including HER2CLIMB-02 and HER2CLIMB-05, in patients with or without brain metastases, and offer their clinical perspective which second-line regimens they typically recommend for their patients with HER2+ mBC.

July 27, 2023

The expert panel switches its focus to endometrial cancer and discusses recent data from clinical trials.

July 20, 2023

Experts introduce the antibody-drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) and discuss clinical trial findings and potential use in special patient populations, such as those with brain metastases.

July 20, 2023

Expert gynecologic oncologists react to data from the MIRASOL trial, which studied mirvetuximab in patients with platinum-resistant ovarian cancer.